Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial

Ibrutinib is effective in patients with chronic lymphocytic leukaemia (CLL); however, treatment resistance remains a problem. Ublituximab is a novel, glycoengineered anti‐CD20 monoclonal antibody with single‐agent activity in relapsed CLL. We report the results of a phase 2 study evaluating combinat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Haematol
Päätekijät: Sharman, Jeff P., Farber, Charles M., Mahadevan, Daruka, Schreeder, Marshall T., Brooks, Heather D., Kolibaba, Kathryn S., Fanning, Suzanne, Klein, Leonard, Greenwald, Daniel R., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Burke, John M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
Haematological Malignancy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299538/
https://ncbi.nlm.nih.gov/pubmed/27982425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14447
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia